KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Free Cash Flow (2016 - 2025)

BeOne Medicines (ONC) has disclosed Free Cash Flow for 11 consecutive years, with $412.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 414.1% to $412.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 794.57% increase, with the full-year FY2025 number at $1.1 billion, up 607.38% from a year prior.
  • Free Cash Flow was $412.1 million for Q4 2025 at BeOne Medicines, up from $408.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $412.1 million in Q4 2025 to a low of -$707.3 million in Q3 2022.
  • A 5-year average of -$167.1 million and a median of -$303.5 million in 2022 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: plummeted 399.07% in 2022, then skyrocketed 414.1% in 2025.
  • BeOne Medicines' Free Cash Flow stood at $221.9 million in 2021, then tumbled by 298.12% to -$439.5 million in 2022, then rose by 13.87% to -$378.6 million in 2023, then skyrocketed by 121.17% to $80.2 million in 2024, then surged by 414.1% to $412.1 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Free Cash Flow are $412.1 million (Q4 2025), $408.4 million (Q3 2025), and $265.7 million (Q2 2025).